Karus (UK)

Karus is developing a new family of highly potent, well-tolerated, optimised HDAC inhibitors (OS-HDI) thought to be the most potent histone deacetylase (HDAC) inhibitors known with a distinctively prolonged pharmacodynamic effect. Karus has two development programs, one in cancer and one in psoriasis and has initiated further programs in other disease areas, including rheumatoid arthritis and organ transplant rejection. For more information, visit www.karustherapeutics.com


Case Studies